BeOne Medicines Ltd. has 4 Schedule 13D or 13G filings on record since 2026-04-16. 1 holder's latest filing reports 5% or more of ordinary shares, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 7.8% | 115,457,154 | SCHEDULE 13D/A, 2026-09-16 | 2026-09-14 |
| Capital International Investors | 4.2% | 65,211,266 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 |
Purpose of Transaction (Item 4)
Baker Bros. Advisors LP
Item 4 of this Amendment is supplemented and amended, as the case may be, as follows: On September 14, 2026, the Adviser exercised options to purchase Ordinary Shares or ADS ("Share Options") to purchase 30,768 ADS as a result of the exercise of 15,384 Share Options to purchase ADS at $36.83 per ADS (the "Exercised ADS Options") held directly by each of Ranjeev Krishana and Michael Goller, resulting in the acquisition of a total of 30,768 ADS. Messrs. Krishana and Goller, each of whom is a full-time employee of the Adviser, previously served on the Issuer's board of directors (the "Board") as representatives of the Funds. The policy of the Funds and the Adviser does not permit full-time employees of the Adviser to receive compensation for serving as directors of the Issuer, and the Funds are instead entitled to the pecuniary interest in the Exercised ADS Options and any resulting ADS. Messrs. Krishana and Goller, as agents in their capacity as former directors of the Issuer, entered into proceeds agreements (respectively, the "Krishana Proceeds Agreement" and the "Goller Proceeds Agreement" and, collectively, the "Proceeds Agreements") with the Adviser on September 14, 2026. Pursuant to the Proceeds Agreements, Messrs. Krishana and Goller each agreed that, with respect to the Exercised ADS Options and the ADS received as a result of the exercise of the Exercised ADS Options, the Adviser will have dispositive power as well as the ability to control the timing of exercise …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-09-16; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-04-16 | Baker Bros. Advisors LP | 8% | SCHEDULE 13D/A |
| 2026-05-14 | Capital International Investors | 4.2% | SCHEDULE 13G/A |
| 2026-06-15 | Baker Bros. Advisors LP | 8% | SCHEDULE 13D/A |
| 2026-09-16 | Baker Bros. Advisors LP | 7.8% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for BeOne Medicines Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.